Summary:
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE
LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE
PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE
Qualified Participants Must:
• Male or female participants aged 18 to 80 years
•
At least a 1-year history of migraine with or without aura consistent with a diagnosis
Qualified Participants May Receive:
Compensation for time and travel